Alzheimer's Disease Researchers Solve Mystery of Beguiling Protein
Immune cell receptors helps and harms depending on disease stage
Leading neuroscientists have clarified the role of a controversial immune system protein in Alzheimer’s disease, showing it has opposing effects in early and late stages of the disease. Their discovery unites previous studies that left researchers conflicted and showed the protein both exacerbates and ameliorates disease symptoms. The updated model of disease progression also highlights the need to align certain therapies with disease stages. The protein in question is TREM2, or triggering receptor expressed on myeloid cells 2. It sits on the surfaces of immune cells in the brain and helps sense changes in the brain microenvironment. During Alzheimer’s disease, TREM2 helps recruit immune cells to respond to toxic “amyloid” protein plaques that often form in the brain. But, the sudden influx of cells can also cause destructive effects in the brain and make things worse.
Click here to read more.
Microsurgery Course Zurich
March 29-April 1, 2017; Zurich, Switzerland
12th World Congress on Brain Injury
March 29-April 1, 2017; New Orleans
2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.
Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany
Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.
Be the first to reply using the above form.